The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
Study Details
Study Description
Brief Summary
The goal of this observational study is to explore whether ctDNA dynamic monitoring plus AI-based pathology can more effectively predict the therapeutic effect of neoadjuvant chemoimmunotherapy for resectable lung squamous cell carcinoma, so as to accurately guide clinical diagnosis and treatment.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study is a single-center, observational, non-interventional, prospective study. 50 patients diagnosed with lung squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy (ranging 2 to 4 cycles) will be planned to be enrolled in the study. Pre-treatment biopsy tissues of enrolled patients will be collected for whole exon sequencing (WES) testing, and personalized detection panel will be customized based on WES testing results. Peripheral blood will be collected 1 day before each cycle of neoadjuvant therapy, 1 day before surgery, 3 days after surgery, and 3 weeks after surgery for ctDNA testing. In addition, the prediction model of AI-based pathology will be constructed by AI deep learning based on pathological sections of pre-treatment biopsy tissues. All inclued patients will be regularly followed up for at least 5 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with lung Squamous Cell Carcinoma receiving neoadjuvant chemoimmunotherapy
|
Diagnostic Test: WES and ctDNA detection
WES and ctDNA detection
|
Outcome Measures
Primary Outcome Measures
- Pathologic completet response (pCR) rate [Up to 1 year]
pCR rate is defined as the percentage of participants having an absence of residual tumor cells in resected lung specimens and lymph nodes following completion of neoadjuvant therapy.
- ctDNA resolution [Up to 2 years]
ctDNA resolution is defined as the change or resolution in tumor-derived DNA found in the bloodstream from diagnosis to after neoadjuvant therapy and after surgery, correlated with pathologic complete response (pCR)
- Development of computer algorithm to identify pCR features [From retrospective data collection to algorithm development (6 month)]
Development of computer algorithm to identify pCR features
- Validation of computer algorithm to identify pCR features [From prospective data collection to algorithm validation (6 months)]
Validation of computer algorithm to identify pCR features
Secondary Outcome Measures
- Major pathological response (MPR) rate [Up to 1 year]
MPR rate is defined as the percentage of participants having ≤10% viable tumor cells in the resected primary tumor and resected lymph nodes following completion of neoadjuvant therapy.
- Objective response rate(ORR) [Up to 1 year]
The proportion of patients achieved complete or patial remission(Imageological) according to RECIST 1.1 prior to definitive surgery.
- Adverse events (AEs) [Up to 5 years]
Number of participants experiencing AEs will be recorded. An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Perioperative complications rate [Up to 3 years]
Number of participants experiencing perioperative complications will be recorded.
- Health-related Quality of Life [Up to 5 years]
Health-related Quality of Life will be assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) version 3.0, the EORTC Quality of Life Questionnaire in Lung Cancer (EORTC QLQ-LC13), and the European Quality of Life 5 Dimensions (EQ-5D) questionnaire.
- Perioperative pain evaluation [Up to 3 years]
Perioperative pain evaluation assessed by a numeric rating scale (NRS)
- Disease free survival (DFS) [Up to 5 years]
From the date of surgery to any of the following events: disease progression, disease recurrence or death from any cause.
- Overall survival (OS) [Up to 5 years]
From the date of participated in study to the date of death.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histopathology or cytology confirmed the lung squamous cell carcinoma
-
Age ranging from 18 to 75
-
Agree to participate in this study and sign an informed consent form
-
Treatment-naive tumor
-
According to the American Joint Committee on Cancer (AJCC) eighth edition of the Lung Cancer Staging Manual, the clinical stage is stage II-IIIb resectable or potentially resectable tumor
-
Sufficient tissue/blood samples are available to meet research requirements
-
The ECOG PS score is 0-1
Exclusion Criteria:
-
Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent form
-
Non-squamous NSCLC
-
Unresectable IIIa-IIIb tumor
-
Patients with solid organ or blood system transplantation
-
Previous use of CTLA-4, PD-1, or PD-L1 immune checkpoint inhibitors
-
Patients with interstitial lung disease
-
Patients with acute or chronic infectious disease
-
Pregnant and lactating women
-
Patients who have undergone other clinical drug trials
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Thoracic Surgery, Second Xiangya Hospital of Central South University, China | Changsha | Hunan | China | 410011 |
Sponsors and Collaborators
- Second Xiangya Hospital of Central South University
- Shanghai OrigiMed Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LYF2022198